Vertex Pharmaceuticals Inc VRTX:NASDAQ

Earnings Announcement Next Earnings date is expected on 10/23/2019
Last Price$176.23NASDAQ Previous Close - Last Trade as of 4:00PM ET 10/18/19

Today's Change0(0.00%)
Bid (Size)$176.20 (5)
Ask (Size)$176.28 (2)
Day Low / HighN/A - N/A
Volume1.1 M

View Biotechnology IndustryPeer Comparison as of 10/18/2019


Vertex Pharmaceuticals Inc ( NASDAQ )

Price: $176.23
Change: -1.49 (0.84%)
Volume: 1.1 M
4:00PM ET 10/18/2019

Illumina Inc ( NASDAQ )

Price: $309.44
Change: -1.11 (0.36%)
Volume: 598.1 K
4:00PM ET 10/18/2019

Biogen Inc ( NASDAQ )

Price: $220.06
Change: -5.54 (2.46%)
Volume: 2.8 M
4:00PM ET 10/18/2019

Regeneron Pharmaceuticals Inc ( NASDAQ )

Price: $300.20
Change: +0.01 (0.00%)
Volume: 530.0 K
4:00PM ET 10/18/2019

Agilent Technologies Inc ( NYSE )

Price: $74.57
Change: -0.35 (0.47%)
Volume: 2.1 M
6:30PM ET 10/18/2019

Read more news Recent News

Vertex Gets Positive CHMP Opinion for Expanded Label for Cystic Fibrosis Drug
11:56AM ET 10/18/2019 MT Newswires

Vertex Pharmaceuticals (VRTX) said Friday that the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended the approval...

Analyst Actions: BofA Merrill Lynch Reinstates Vertex Pharmaceuticals at Buy With $220 Price Target
9:10AM ET 10/17/2019 MT Newswires

Vertex Pharmaceuticals (VRTX) has an average rating among analysts of buy, with an average price target of $213. Price: 176.09, Change: -0.05, Percent...

Research Alert: CFRA Raises Opinion On Shares Of Vertex Pharmaceuticals, Inc. To Buy From Hold
2:15PM ET 10/09/2019 MT Newswires

CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as...

Insider Trends: Selling By Insiders Lingers at Vertex Pharmaceuticals
4:27PM ET 10/03/2019 MT Newswires

Ourania Tatsis, SVP, Cro, sold 632 shares in Vertex Pharmaceuticals (VRTX) for $106,247 on Oct 01, 2019. Tatsis, after the transactions delineated in the...

Company Profile

Business DescriptionVertex Pharmaceuticals, Inc. engages in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases. It focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA. View company web site for more details
Address50 Northern Avenue
Boston, Massachusetts 02210
Number of Employees2,500
Recent SEC Filing10/17/20194
Chairman, President & Chief Executive OfficerJeffrey M. Leiden
Chief Financial Officer & Executive Vice PresidentCharles F. Wagner
Chief Scientific Officer & EVP-Global ResearchDavid Matthew Altshuler
Chief Medical Officer & Executive Vice PresidentReshma Kewalramani

Company Highlights

Price Open$180.25
Previous Close$177.72
52 Week Range$151.80 - 195.81
Market Capitalization$45.3 B
Shares Outstanding257.0 M
SectorHealth Technology
Next Earnings Announcement10/23/2019

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / Earnings20.35
Earnings per Share$8.44
Beta vs. S&P 500N/A
Revenue$3.0 B
Net Profit Margin64.55%
Return on Equity51.71%

Analyst Ratings as of 10/16/2019

Consensus RecommendationConsensus Icon
Powered by Factset